| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 01/25/2000 | CA2001436C Carboxylic acid derivatives |
| 01/24/2000 | CA2277703A1 New 2-amino, 4-alkylamino pyrimidine 3-oxides and composition comprising them |
| 01/20/2000 | WO2000003248A1 Method for identifying a presenilinase inhibitor |
| 01/20/2000 | WO2000003015A2 Human transport protein homologs |
| 01/20/2000 | WO2000003004A2 Presenilin 2 specific ribozyme |
| 01/20/2000 | WO2000002923A1 Method of treating disorders by modulating the interaction of natural killer receptors on t cells with their respective ligands |
| 01/20/2000 | WO2000002860A1 2-aminopyridine erivatives, their use as medicines and pharmaceutical compositions containing them |
| 01/20/2000 | WO2000002857A1 Bis-indole derivatives and their use as antiinflammatory agents |
| 01/20/2000 | WO2000002587A1 Cancer treatment methods using therapeutic conjugates that bind to aminophospholipids |
| 01/20/2000 | WO2000002584A2 Cancer treatment methods using antibodies to aminophospholipids |
| 01/20/2000 | WO2000002583A1 Method of treating disorders by modulating the interaction of natural killer receptors on t cells with their respective ligands |
| 01/20/2000 | WO2000002582A2 Treatment of celiac disease with interleukin-15 antagonists |
| 01/20/2000 | WO2000002579A2 Component b as angiogenic agent in combination with human growth factors |
| 01/20/2000 | WO2000002577A1 Therapeutic use of uncoupling protein hhfcw60 |
| 01/20/2000 | WO2000002558A1 Use of prenyltransferase inhibitors for preparing a medicine for treating pathologies resulting from heterotrimeric g protein membrane fixation |
| 01/20/2000 | WO2000002557A1 Use of an inhibitor of cytochrome p450 optionally combined with an antifungal agent for treating mycoses |
| 01/20/2000 | WO2000002549A2 Composition for and method of treating neurological disorders |
| 01/20/2000 | WO2000002548A2 Inhibitors of proteasomal activity for stimulating bone and hair growth |
| 01/20/2000 | WO2000002543A2 Antihypersensitive combination of valsartan and calcium channel blocker |
| 01/20/2000 | WO2000002542A2 Agents with an antidepressive effect containing pramipexol and an additional antidepressant drug |
| 01/20/2000 | WO2000002541A1 Transdermal plaster containing at least one active ingredient which influences blood serum lipid levels |
| 01/20/2000 | WO2000002520A2 T-lymphocyte exchange |
| 01/20/2000 | WO2000002500A1 Cardiac disease treatment device and method |
| 01/20/2000 | WO1999051742A3 Dadd, death activator death domain protein |
| 01/20/2000 | WO1999045908A3 Anti-viral uses of leflunomide products |
| 01/20/2000 | WO1999040115A9 COMPOSITIONS AND METHODS TO INHIBIT FORMATION OF THE C5b-9 COMPLEX OF COMPLEMENT |
| 01/20/2000 | WO1999038964A3 Promoter regions of the mouse and human telomerase rna component genes |
| 01/20/2000 | WO1999038472A3 Topical vasodilatory gel composition and methods of use and production |
| 01/20/2000 | CA2337261A1 Use of prenyltransferase inhibitors for preparing a medicine for treating pathologies resulting from heterotrimeric g protein membrane fixation |
| 01/20/2000 | CA2337258A1 2-aminopyridine derivatives, their use as medicines and pharmaceutical compositions containing them |
| 01/20/2000 | CA2337164A1 Cardiac disease treatment device and method |
| 01/20/2000 | CA2335254A1 Bis-indole derivatives and their use as antiinflammatory agents |
| 01/20/2000 | CA2333923A1 Treatment of celiac disease with interleukin-15 antagonists |
| 01/20/2000 | CA2332497A1 Presenilin 2 specific ribozyme |
| 01/20/2000 | CA2332344A1 Method for identifying a presenilinase inhibitor |
| 01/20/2000 | CA2332307A1 Human transport protein homologs |
| 01/20/2000 | CA2331789A1 Cancer treatment methods using therapeutic conjugates that bind to aminophospholipids |
| 01/19/2000 | EP0972521A1 Pharmaceutical composition containing stimulators of interferon-gamma |
| 01/19/2000 | EP0972518A2 Exchange of T lymphocytes |
| 01/19/2000 | EP0972517A2 Use of 1,2,4-benzotriazine oxides for the preparation of a medicament for the treatment of tumours |
| 01/19/2000 | EP0972200A1 Screening and treatment using complement regulator or receptor proteins |
| 01/19/2000 | EP0972075A2 Methods for assessing cardiovascular status and compositions for use thereof |
| 01/19/2000 | EP0972053A1 Novel human serine carboxypeptidase |
| 01/19/2000 | EP0972052A1 Keratinocyte derived kallikrein |
| 01/19/2000 | EP0972041A1 Novel human delta3 compositions and therapeutic and diagnostic uses therefor |
| 01/19/2000 | EP0972035A1 Human tumor suppressor |
| 01/19/2000 | EP0972027A1 Human c5a-like receptor |
| 01/19/2000 | EP0972025A1 I-flice, a novel inhibitor of tumor necrosis factor receptor-1 and cd-95 induced apoptosis |
| 01/19/2000 | EP0972022A2 Polynucleotides and polypeptides encoding receptors |
| 01/19/2000 | EP0972021A1 Extracellular/epidermal growth factor like protein |
| 01/19/2000 | EP0972020A1 Insulin-like growth factor agonist peptides |
| 01/19/2000 | EP0971949A1 Complexes and combinations of fetuin with therapeutic agents |
| 01/19/2000 | EP0971894A1 Nicotinamide derivatives |
| 01/19/2000 | EP0971745A2 Gel delivery vehicles for anticellular proliferative agents |
| 01/19/2000 | EP0971744A2 COMBINATION THERAPY EMPLOYING ILEAL BILE ACID TRANSPORT INHIBITING BENZOTHIEPINES AND HMG Co-A REDUCTASE INHIBITORS |
| 01/19/2000 | EP0971743A1 Stabilized medicaments containing cysteinyl derivatives |
| 01/19/2000 | EP0971735A1 Methods and compositions for treating inflammatory bowel disease |
| 01/19/2000 | EP0971730A2 Assay for ligands to tyrosine kinase receptors |
| 01/19/2000 | EP0971715A1 Mixtures of at least two reverse transcriptase inhibitors and hydroxycarbamide, in particular for inhibiting retroviral spread |
| 01/19/2000 | EP0971713A1 Use of cholinesterase inhibitors to treat disorders of attention |
| 01/19/2000 | EP0971712A1 Compositions for the inhibition of bone resorption |
| 01/19/2000 | EP0971698A1 Aerosolized hydrophobic drug |
| 01/19/2000 | EP0601164B1 Methods for treating viral infections |
| 01/19/2000 | CN1241908A Endoparasiticidal and ectoparasiticidal agents |
| 01/19/2000 | CN1241632A Gene engineering adenovirus and its application |
| 01/18/2000 | US6015883 Amino acid sequence of purified chemokine polypeptide; treatment of immune deficiency diseases, autoimmune diseases, allergies or asthma; anticarcinogenic/antiinflammatory/ antiarthritic agents |
| 01/18/2000 | US6015835 Methods of inducing analgesia or anesthesia and treating or preventing ischemic injury of tissues in general |
| 01/18/2000 | US6015834 Administering chelate compound; antiischemic, antiepileptic, and wound healing agents; treating brain and nervous system disorders |
| 01/18/2000 | US6015828 Chemical modification of chloride channels as a treatment for cystic fibrosis and other diseases |
| 01/18/2000 | US6015827 Benzoxazole-4-carboxamides and their use in inhibiting poly (adp-ribose) polymerase activity and improving cytotoxic effectiveness of cytotoxic drugs or radiotherapy |
| 01/18/2000 | US6015819 Administering adrenergic blocking agent; reduction of orthostatic fall in blood pressure side effect; fda orange book listed patent for silodosin |
| 01/18/2000 | US6015805 Potent antiprogestational activity and are useful in the treatment of fibroids, endometriosis, cervical ripening prior to delivery, hormone replacement therapy and in the control of fertility. |
| 01/18/2000 | US6015797 Adenosinergic agonist containing pharmaceutical composition with analgesic activity |
| 01/18/2000 | US6015796 Polysaccharide derived from a hot water extract of human-type tubercle bacillus and (b) a nucleoside-type anti-hiv agent. |
| 01/18/2000 | US6015793 Use of tagatose to enhance key blood factors |
| 01/18/2000 | US6015790 Methods and compositions for treating rheumatoid arthritis |
| 01/18/2000 | US6015569 Polycyclic aromatic compounds and pharmaceutical/cosmetic compositions comprised thereof |
| 01/18/2000 | US6015562 Antitumor agents |
| 01/18/2000 | US6015558 Treatment of insulin resistance in obesity linked type II diabetes using antagonists to TNF-α function |
| 01/18/2000 | US6015556 Cytotoxic drug therapy |
| 01/18/2000 | US6015555 Transferrin receptor specific antibody-neuropharmaceutical or diagnostic agent conjugates |
| 01/13/2000 | WO2000002051A1 Trifunctional reagent for conjugation to a biomolecule |
| 01/13/2000 | WO2000002050A1 Trifunctional reagent for conjugation to a biomolecule |
| 01/13/2000 | WO2000001818A1 Human emr1-like g protein coupled receptor |
| 01/13/2000 | WO2000001811A1 Kv6.2, A VOLTAGE-GATED POTASSIUM CHANNEL SUBUNIT |
| 01/13/2000 | WO2000001805A1 Cells and animals deficient in protein kinase c epsilon |
| 01/13/2000 | WO2000001716A2 Vasculoprotector |
| 01/13/2000 | WO2000001714A1 Efflux pump inhibitors |
| 01/13/2000 | WO2000001713A2 Diacylglycerol acyl transferase proteins |
| 01/13/2000 | WO2000001415A2 Use of inhibitors of protein kinase c epsilon to treat pain |
| 01/13/2000 | WO2000001414A1 Use of texaphyrins in macrophage-mediated disease |
| 01/13/2000 | WO2000001410A1 Methods of inhibiting proliferative diseases by inhibiting tgf-beta mediated angiogenesis |
| 01/13/2000 | WO2000001404A1 Compositions and methods for $i(in vitro) fertilization |
| 01/13/2000 | WO2000001400A1 Compositions comprising endotoxin neutralizing protein and derivatives and uses thereof |
| 01/13/2000 | WO2000001378A1 Methods and compositions for treatment of disorders associated with chlamydial and similar bacterial infection |
| 01/13/2000 | WO2000001377A2 Nalmefene in combination with opioid analgesics |
| 01/13/2000 | WO2000001376A2 Pharmaceutical compositions and their uses for treatment of demyelinating disorders |
| 01/13/2000 | WO2000001349A2 Cavity induced allosteric modification of intermolecular interactions and methods of identifying compounds that effect the same |
| 01/13/2000 | WO2000001238A1 Methods for eradication of nanobacteria |
| 01/13/2000 | WO1999059628A3 Combination therapy for the treatment of tumors |